This week on the Business of Biotech, Cyriac Roeding talks about his 'BioAI' company Earli, why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign wealth fund could support drug devlpmt leadership at home. Link to full episode: lifescienceleader.com/doc/re…
Check out the January 2023 issue of Life Science Leader, including interviews with Verve Therapeutics founder and CEO Sekar Kathiresan and #CBER director Peter Marks. Happy New Year! lnkd.in/gggauDAb
With a growing number of irons in the fire, the possibility for a #T1D cure is getting closer: lifescienceleader.com/doc/ti…
"What to expect at #BioFuture22: Join us for 600+ Life Sciences Leaders and Investors, 80+ Innovative Presenting Companies, Plenaries, Workshops, Networking Events, & One-to-One Meetings with Investors. Visit our website for more info! #BioFuture2022 biofuture.com/?utm_LSL"
@MAPSPBC's CEO Amy Emerson talks about working toward the near-term potential of an FDA approved MDMA-assisted therapy for #PTSD patients in our May cover story (free with sign-up): lifescienceleader.com/doc/a-…
Semaglutide moves forward in obesity -- check out In Vivo's 'sema' brand spotlight (sub req.) on a drug with big ambitions, from obesity to NASH and Alzheimer's disease: invivo.pharmaintelligence.in…
Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity scrip.pharmaintelligence.inf…
Which biopharma M&A deal was most significant in 2019? In Vivo narrowed it down to five - cast your vote to help us pick the number one deal: invivo.pharmaintelligence.in…
How often can real-world evidence replace clinical trial data? pwc.to/2pap8L7
Part D plans could face increased risk under proposed Part D changes: MedPAC pwc.to/2WRbcR7
Just released! #PwC’s Behind the numbers 2020. Read about the forces influencing medical cost trend from PwC’s Health Research Institute: pwc.to/2XZB1j7 #healthresearch
New policy proposals, regulations and investigations into prescription drug pricing practices are changing the way medicines are bought and sold around the world. Check out HRI's new report on #drugpricing pwc.to/2VtUnQb
1
Drugmakers will have to broadcast prices during TV ads, HHS says pwc.to/2E0XZyn
Part D insurers get CMS offer to protect against 2020 premium hikes pwc.com/us/en/industries/hea…
PBM executives oppose rebate retool in congressional hearing pwc.com/us/en/industries/hea…
Pharma companies/CROs pushed by FDA toward risk-based trial monitoring pwc.com/us/en/industries/hea…
Advanced analytics fuel tomorrow’s commercial strategy for drugs and devices pwc.com/us/en/industries/hea…
Washington aims strong spotlight on nation’s drug prices pwc.to/2BokBHS
1
HHS proposes major shift to protections for Part D and Medicaid MCO drug rebates pwc.to/2GgWpv2
PWC survey finds 54 percent of consumers willing to use digital treatment. shar.es/ammyJP via @MobiHealthNews


